Also, in the back of my mind I recalled that part of the Cephalon deal was neuro diseases - and sure enough, MSB has a granted US patent for MS (US 10,206,951)!!
And that patent covers cells from both allogenic or autologous sources, if my interpretation of the word autogeneic is correct, I guess it makes sense to cover all bases, and perhaps more importantly it covers multipotent or pluripotent cells for good measure.
7. The method of claim 1, wherein the population enriched for STRO-1.sup.+ TNAP.sup.+ multipotential cells is autogeneic or allogeneic.
Further into the claim;
The cellular compositions useful for methods described herein may be administered alone or as admixtures with other cells. Cells that may be administered in conjunction with the compositions of the present disclosure include, but are notlimited to, other multipotent or pluripotent cells or stem cells, or bone marrow cells. The cells of different types may be admixed with a composition of the disclosure immediately or shortly prior to administration, or they may be co-cultured togetherfor a period of time prior to administration.
I wonder if the mention of multipotent or pluripotent cells is also the case for any patents for aGVHD treatments that Mesoblast might hold?
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
Also, in the back of my mind I recalled that part of the...
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.72 |
Change
0.010(0.59%) |
Mkt cap ! $1.113B |
Open | High | Low | Value | Volume |
$1.70 | $1.72 | $1.69 | $395.0K | 231.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 12494 | $1.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.72 | 43851 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 1.375 |
1 | 82 | 1.370 |
1 | 3981 | 1.365 |
7 | 49392 | 1.360 |
1 | 4134 | 1.355 |
Price($) | Vol. | No. |
---|---|---|
1.385 | 247 | 1 |
1.400 | 4328 | 1 |
1.405 | 12000 | 2 |
1.410 | 18724 | 1 |
1.420 | 12000 | 2 |
Last trade - 10.19am 27/11/2024 (20 minute delay) ? |
MSB (ASX) Chart |